Clinical Pediatrics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rapaport, R.
Right arrow Articles by Goldstein, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rapaport, R.
Right arrow Articles by Goldstein, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Pediatrics, Vol. 30, No. 1, 22-27 (1991)
DOI: 10.1177/000992289103000104

*Immune Functions During Treatment of Growth Hormone-Deficient Children with Biosynthetic Human Growth Hormone

Robert Rapaport, MD

Division of Pediatric Endocrinology and Metabolism, Children's Hospital of New Jersey, 15 South Ninth Street, Newark, New Jersey 07107

Bruce Petersen, PhD

Lilly Laboratories for Clinical Research

Kathryn A. Skuza, MD

Children's Hospital of New Jersey, Newark, New Jersey

Melinda Heim, MS

Eli Lilly and Co., Indianapolis, Indiana

Steven Goldstein, MD

Children's Hospital of New Jersey, Newark, New Jersey

Immune functions, including cell surface markers, interieukin-2 receptor levels and responses of lymphocytes to mitogenic stimulation were evaluated in seven growth hormone deficient children ages 4-15 years, during treatment with biosynthetically derived human growth hormone. Treatment resulted in a decrease in % B cells and in % T total cells and also decreases in most individual patients' mitogen responses and interleukin-2 receptor levels. Most of the changes noted were transient and similar to those previously demonstrated during pituitary-derived human growth hormone treatment. Although not resulting in overt clinical manifestations in our patients, we think that potential interactions between growth hormone and immune functions need to be considered by physicians treating children with growth hormone.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?